SCHEMBL4837622

SCHEMBL4837622

CON(C)C(=O)c1cccc(Br)c1C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
HPGD P15428 2/20 0.40
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
AHR P35869 1/20 0.38
ESR1 P03372 2/20 0.36
ESR2 Q92731 2/20 0.36
F2R P25116 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MLYCD O95822 1/20 0.36
LPAR5 Q9H1C0 1/20 0.35
PKM P14618 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HSD17B10 Q99714 1/20 0.34
LMNA P02545 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30705740 1.00 KMT2A (0.41) KMT2AMEN1TDP1HPGDRAB9A
SCHEMBL306847 0.84 HPGD (0.54) KMT2AMEN1TDP1HPGDRAB9A
SCHEMBL2285021 0.83 HPGD (0.40) KMT2AMEN1TDP1HPGDRAB9A
SCHEMBL30292603 0.83 HPGD (0.39) KMT2AMEN1TDP1HPGDRAB9A
SCHEMBL155883 0.82 MEN1 (0.41) KMT2AMEN1TDP1HPGDRAB9A
SCHEMBL144818 0.82 KMT2A (0.49) KMT2AMEN1TDP1HPGDAHR
SCHEMBL6269942 0.82 HSD17B10 (0.39) KMT2AMEN1TDP1HPGDRAB9A
SCHEMBL15761206 0.80 UTS2R (0.43) KMT2AMEN1HPGDRAB9APKM
SCHEMBL21401288 0.80 ESR1 (0.55) KMT2AMEN1TDP1RAB9ANPC1
SCHEMBL14381951 0.80 ESR1 (0.36) KMT2AMEN1TDP1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382290-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-12-18 US disclosed
US-20250270220-A1 SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2025-08-28 US disclosed
US-12304915-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2025-05-20 US disclosed
US-20250059182-A1 SOS1 INHIBITORS MIRATI THERAPEUTICS, INC 2025-02-20 US disclosed
US-20250042857-A1 SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure HAIHE BIOPHARMA CO., LTD. (CN) 2025-02-06 US disclosed
EP-4410790-A1 SOS1 INHIBITORS HAVING PYRIDO SIX-MEMBERED RING STRUCTURE Haihe Biopharma Co., Ltd. (CN) 2024-08-07 EP disclosed
WO-2023250165-A1 SALTS OF SOS1 INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-28 WO disclosed
WO-2023246837-A1 CLASS OF COMPOUNDS HAVING PYRIMIDO-SIX-MEMBERED RING STRUCTURE, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND USE THEREOF 上海海和药物研究开发股份有限公司 2023-12-28 WO disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-11702418-B2 SOS1 inhibitors Mirati Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-7338960-B2 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hPPAR activators SMITHKLINE BEECHAM CORPORATION (US) 2008-03-04 US disclosed
EP-1513526-B1 PHENYLALKANOIC ACID AND PHENYLOXYALKANOIC ACID DERIVATIVES AS HPPAR ACTIVATORS SMITHKLINE BEECHAM CORP (US) 2007-11-07 EP disclosed
US-7138530-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-7109354-B2 Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2006-09-19 US disclosed
US-20060089394-A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators SMITHKLINE BEECHAM CORPORATION 2006-04-27 US disclosed
EP-1549632-A4 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS DIMENSIONAL PHARM INC (US) 2005-11-09 EP disclosed
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions SUBASINGHE NALIN 2005-10-20 US disclosed
EP-1549632-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2005-07-06 EP disclosed
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-01-15 US disclosed
WO-2003099805-A1 NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234081-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R KMT2A 4363/4885MEN1 1309/4885TDP1 4176/4885
US-20250042857-A1 SOS1 Inhibitor With Pyrido-Fused Six-Membered Ring Structure SOS1, MEN1, BRCA1 KMT2A 4031/4885MEN1 2/4885TDP1 807/4885
US-20040009995-A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions C5, C9, C1R KMT2A 4508/4885MEN1 1088/4885TDP1 3250/4885
US-20060089394-A1 Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators LIPA, PNLIP, CEL KMT2A 2979/4885MEN1 4719/4885TDP1 2140/4885
US-20250382290-A1 SALTS OF SOS1 INHIBITORS SOS1, SOS2, SOST KMT2A 3165/4885MEN1 119/4885TDP1 2167/4885
US-12304915-B2 SOS1 inhibitors SOS1, SOS2, SAV1 KMT2A 3283/4885MEN1 214/4885TDP1 2544/4885
US-20250059182-A1 SOS1 INHIBITORS SOS1, SOS2, SOST KMT2A 3302/4885MEN1 184/4885TDP1 2139/4885
US-20250270220-A1 SOS1 INHIBITORS SOS1, SOS2, SAV1 KMT2A 3283/4885MEN1 214/4885TDP1 2544/4885
US-11702418-B2 SOS1 inhibitors SOS1, SOS2, SOST KMT2A 3302/4885MEN1 184/4885TDP1 2139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.